Relatively novel pharmaceuticals – particularly for chronic conditions like obesity, cardiovascular disease and cancer – are already reshaping the balance between surgical intervention and non-invasive treatment. While headlines often focus on “blockbuster” drug approvals or updated clinical guidelines (e.g., screening recommendations), GLP-1s, which were theorized in 1906 and invented in 1986, demonstrate the potential magnitude of shifts in care delivery from a single therapeutic, which has important implications for provider financial viability, patient safety and access to care. As consumer expectations evolve and new therapies emerge, providers must confront a challenging question: What happens if and when surgery is no longer the default standard of care?
Read the full article: Surgical Procedures Are Increasingly Imperiled by New Pharmaceuticals //
Source: https://www.trillianthealth.com/market-research/studies/surgical-procedures-imperiled-by-pharmaceuticals